Lequn Bao

机构：Hubei Cancer Hospital

发表论文 19 篇 · 总被引 529 次 · h-index 9

代表论文

• Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study (2023 · The Lancet Oncology · 被引 284)
• 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming (2019 · Biomedicine & Pharmacotherapy · 被引 66)
• Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial (2024 · Journal of Clinical Oncology · 被引 51)
• ORC6, Negatively Regulated by miR-1-3p, Promotes Proliferation, Migration, and Invasion of Hepatocellular Carcinoma Cells (2021 · Frontiers in Cell and Developmental Biology · 被引 33)
• Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study (2022 · Cancer Medicine · 被引 22)
• MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo (2019 · Biochemical and Biophysical Research Communications · 被引 22)